(NASDAQ: ATAI) Ataibeckley's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Ataibeckley's earnings in 2026 is -$663,398,000.On average, 16 Wall Street analysts forecast ATAI's earnings for 2026 to be -$150,212,003, with the lowest ATAI earnings forecast at -$173,185,603, and the highest ATAI earnings forecast at -$127,569,753. On average, 14 Wall Street analysts forecast ATAI's earnings for 2027 to be -$160,410,220, with the lowest ATAI earnings forecast at -$176,793,637, and the highest ATAI earnings forecast at -$119,838,252.
In 2028, ATAI is forecast to generate -$154,519,553 in earnings, with the lowest earnings forecast at -$198,441,837 and the highest earnings forecast at -$69,583,501.